. .. , 2.3! Caractéristiques de l'atteinte rénale à la phase aiguë

. .. !-conclusion,

!. .. Bibliographie, 72! 8.1! Annexe 1 : Fiche information Santé Publique France

C. Gasser, E. Gautier, and A. Steck, , 1955.

P. I. Tarr, C. A. Gordon, and W. L. Chandler, Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome, Lancet Lond Engl, vol.365, pp.1073-1086, 2005.

F. Fakhouri, J. Zuber, V. Frémeaux-bacchi, and C. Loirat, Haemolytic uraemic syndrome, The Lancet, vol.390, pp.681-696, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02155934

M. Bruyand, P. Mariani-kurkdjian, L. Hello, and S. , Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, vol.24, 2007.
URL : https://hal.archives-ouvertes.fr/hal-02153948

C. Picard, S. Burtey, and C. Bornet, Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome, Pathol Biol, vol.63, pp.136-143, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01460643

M. Bruyand, P. Mariani-kurkdjian, and M. Gouali, Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection, Med Mal Infect, vol.48, pp.167-174, 2018.

S. E. Majowicz, E. Scallan, and A. Jones-bitton, Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis, Foodborne Pathog Dis, vol.11, pp.447-455, 2014.

G. Jones, P. Mariani-kurkdjian, and S. Lefevre,

M. Khalid and S. Andreoli, Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS), Pediatr Nephrol Berl Ger, 2018.

H. Trachtman, C. Austin, M. Lewinski, and R. Stahl, Renal and neurological involvement in typical Shiga toxin-associated HUS, Nat Rev Nephrol, vol.8, pp.658-669, 2012.

S. Nathanson, T. Kwon, and M. Elmaleh, Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome, Clin J Am Soc Nephrol CJASN, vol.5, pp.1218-1228, 2010.

E. G. Gallo and C. A. Gianantonio, Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome, Pediatr Nephrol Berl Ger, vol.9, pp.117-119, 1995.

K. J. Eriksson, S. G. Boyd, and R. C. Tasker, Acute neurology and neurophysiology of haemolytic-uraemic syndrome, Arch Dis Child, vol.84, pp.434-435, 2001.

K. J. Sheth, H. M. Swick, and N. Haworth, Neurological involvement in hemolyticuremic syndrome, Ann Neurol, vol.19, pp.90-93, 1986.

S. Grodinsky, A. Telmesani, and W. L. Robson, Gastrointestinal manifestations of hemolytic uremic syndrome: recognition of pancreatitis, J Pediatr Gastroenterol Nutr, vol.11, pp.518-524, 1990.

P. Eckart, M. Guillot, and M. Jokic, , 1999.

, Arch Pediatr Organe Off Soc Francaise Pediatr, vol.6, pp.430-433

I. Abu-arafeh, E. Gray, and G. Youngson, Myocarditis and haemolytic uraemic syndrome, Arch Dis Child, vol.72, pp.46-47, 1995.

P. E. Birk, S. Chakrabarti, A. G. Lacson, and M. R. Ogborn, Cardiac tamponade as a terminal event in the hemolytic uremic syndrome in childhood, Pediatr Nephrol Berl Ger, vol.8, pp.754-755, 1994.

D. Rigamonti and G. D. Simonetti, Direct cardiac involvement in childhood hemolyticuremic syndrome: case report and review of the literature, Eur J Pediatr, vol.175, pp.1927-1931, 2016.

M. Thayu, W. L. Chandler, and S. Jelacic, Cardiac ischemia during hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.18, pp.286-289, 2003.

L. S. Keir, S. D. Marks, and J. J. Kim, Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies, Drug Des Devel Ther, vol.6, pp.195-208, 2012.

R. A. Exeni, R. J. Fernandez-brando, and A. P. Santiago, Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS), 2018.

, Pediatr Nephrol Berl Ger, vol.33, pp.2057-2071

M. Morigi, S. Buelli, and C. Zanchi, Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling, Am J Pathol, vol.169, pp.1965-1975, 2006.

C. Silberstein, P. Creydt, V. , and G. E. , Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2, Pediatr Nephrol Berl Ger, vol.23, pp.1981-1990, 2008.

K. Kaneko, N. Kiyokawa, and Y. Ohtomo, Apoptosis of renal tubular cells in, 2001.

, Shiga-toxin-mediated hemolytic uremic syndrome, Nephron, vol.87, pp.182-185

T. Kodama, K. Nagayama, and K. Yamada, Induction of apoptosis in human renal, 1999.

C. J. Cobeñas, P. S. Bresso, and L. L. Lombardi, Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.30, pp.2115-2119, 2015.

P. R. Walsh and S. Johnson, Treatment and management of children with haemolytic uraemic syndrome, Arch Dis Child, vol.103, pp.285-291, 2018.

A. Balestracci, S. M. Martin, and I. Toledo, Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.28, pp.919-925, 2013.

K. Grif, M. P. Dierich, H. Karch, and F. Allerberger, Strain-specific differences in the, 1998.

, Dis Off Publ Eur Soc Clin Microbiol, vol.17, pp.761-766

M. Guirro, R. Piazza, R. L. De-souza, and B. Guth, Humoral immune response to, 2014.

, Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls, BMC Infect Dis, vol.14, p.320

M. Rivas, I. Chinen, E. Miliwebsky, and M. Masana, Risk Factors for Shiga Toxin, 2014.

, Producing Escherichia coli-Associated Human Diseases. Microbiol Spectr, vol.2

C. S. Wong, J. C. Mooney, and J. R. Brandt, Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.55, pp.33-41, 2012.

K. E. Smith, P. R. Wilker, and P. L. Reiter, Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Pediatr Infect Dis J, vol.31, pp.37-41, 2012.

M. E. Seifert and P. I. Tarr, Therapy: Azithromycin and decolonization after HUS, Nat Rev Nephrol, vol.8, pp.317-318, 2012.

M. Nitschke, F. Sayk, and C. Härtel, Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4, JAMA, vol.307, pp.1046-1052, 2012.


U. Buchholz, H. Bernard, and D. Werber, German outbreak of Escherichia coli O104:H4 associated with sprouts, N Engl J Med, vol.365, pp.1763-1770, 2011.

G. Ardissino, F. Tel, and I. Possenti, , 2016.

, Hemolytic Uremic Syndrome. Pediatrics, vol.137

B. Michon, A. Moghrabi, and R. Winikoff, Complications of apheresis in children, 2007.

, Transfusion (Paris), vol.47, pp.1837-1842

C. Loirat, F. Beaufils, and E. Sonsino, , 1984.

, Arch Fr Pediatr, vol.41, pp.15-19

R. Van-damme-lombaerts, W. Proesmans, and B. Van-damme, Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study, J Pediatr, vol.113, pp.913-918, 1988.

M. G. Coulthard, An evaluation of treatment with heparin in the haemolyticuraemic syndrome successfully treated by peritoneal dialysis, Arch Dis Child, vol.55, pp.393-397, 1980.

W. L. Robson, G. H. Fick, T. Jadavji, and A. K. Leung, The use of intravenous, 1991.

G. J. Schwartz, A. Muñoz, and M. F. Schneider, New equations to estimate GFR in children with CKD, J Am Soc Nephrol JASN, vol.20, pp.629-637, 2009.

C. Pietrement, E. Allain-launay, and J. Bacchetta, Diagnosis and management of chronic kidney disease in children: Guidelines of the French Society of Pediatric Nephrology, Arch Pediatr Organe Off Soc Francaise Pediatr, vol.23, pp.1191-1200, 2016.

T. Ninchoji, K. Nozu, and K. Nakanishi, Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience, Clin Exp Nephrol, vol.21, pp.889-894, 2017.

B. P. Bell, P. M. Griffin, and P. Lozano, Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections, Pediatrics, vol.100, p.12, 1997.

C. S. Wong, S. Jelacic, and R. L. Habeeb, The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections, N Engl J Med, vol.342, pp.1930-1936, 2000.

N. Safdar, A. Said, R. E. Gangnon, and D. G. Maki, Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis, JAMA, vol.288, pp.996-1001, 2002.

N. Launders, L. Byrne, and C. Jenkins, Disease severity of Shiga toxin-producing, 2016.

E. Coli, O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, BMJ Open, vol.6, p.9933, 2009.

B. R. Weil, S. P. Andreoli, and D. F. Billmire, Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.25, pp.1693-1698, 2010.

C. M. Mcgannon, C. A. Fuller, and A. A. Weiss, Different classes of antibiotics differentially influence shiga toxin production, Antimicrob Agents Chemother, vol.54, pp.3790-3798, 2010.

M. G. Pedersen, C. Hansen, and E. Riise, Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors, J Clin Microbiol, vol.46, pp.2987-2991, 2008.

A. Lapeyraque, M. M. Fremeaux-bacchi, and V. , Eculizumab in severe, 2011.

, Shiga-toxin-associated HUS, N Engl J Med, vol.364, pp.2561-2563

W. Keenswijk, A. Raes, and J. Vande-walle, Is eculizumab efficacious in Shigatoxinassociated hemolytic uremic syndrome? A narrative review of current evidence, Eur J Pediatr, vol.177, pp.311-318, 2018.

L. Percheron, R. Gramada, and S. Tellier, Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study, Pediatr Nephrol, vol.33, pp.1385-1394, 2018.

S. Loos, T. Ahlenstiel, and B. Kranz, An outbreak of Shiga toxin-producing, 2012.

, Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.55, pp.753-759

U. Mahat, R. B. Matar, and S. J. Rotz, Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence, Pediatr Blood Cancer, vol.66, p.27913, 2019.

Y. Delmas, B. Vendrely, and B. Clouzeau, Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, vol.29, pp.565-572, 2014.

S. Loos, W. Aulbert, and B. Hoppe, Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.64, pp.1637-1643, 2017.

C. Monet-didailler, A. Chevallier, and A. Godron-dubrasquet, Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, 2019.

C. Loirat, E. Sonsino, and N. Hinglais, Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology, Pediatr Nephrol Berl Ger, vol.2, pp.279-285, 1988.

G. Rizzoni, A. Claris-appiani, and A. Edefonti, Plasma infusion for hemolyticuremic syndrome in children: results of a multicenter controlled trial, J Pediatr, vol.112, pp.284-290, 1988.

E. Colic, H. Dieperink, K. Titlestad, and M. Tepel, Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study, Lancet Lond Engl, vol.378, pp.1089-1093, 2011.

C. Combe, H. Bui, and V. De-précigout, Immunoadsorption in patients with haemolytic uraemic syndrome, Lancet Lond Engl, vol.379, pp.517-518, 2012.

A. Greinacher, S. Friesecke, and P. Abel, Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial, Lancet Lond Engl, vol.378, pp.1166-1173, 2011.

B. Flam, P. Sackey, and A. Berge, Diarrhea-associated hemolytic uremic Nephrol, vol.29, pp.711-714, 2016.

J. M. Spinale, R. L. Ruebner, L. Copelovitch, and B. S. Kaplan, Long-term outcomes of, 2013.

, Shiga toxin hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.28, pp.2097-2105

A. X. Garg, R. S. Suri, and N. Barrowman, Long-term renal prognosis of diarrheaassociated hemolytic uremic syndrome: a systematic review, meta-analysis, and metaregression, JAMA, vol.290, pp.1360-1370, 2003.

H. A. Repetto, Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome, Kidney Int Suppl, pp.102-106, 2005.

M. G. Caletti, G. Gallo, and C. A. Gianantonio, Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.10, pp.687-692, 1996.

B. L. Wharram, M. Goyal, and J. E. Wiggins, Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene, J Am Soc Nephrol JASN, vol.16, pp.2941-2952, 2005.

S. J. Shankland, The podocyte's response to injury: role in proteinuria and glomerulosclerosis, Kidney Int, vol.69, pp.2131-2147, 2006.

A. B. Fogo, Mechanisms of progression of chronic kidney disease, Pediatr Nephrol Berl Ger, vol.22, pp.2011-2022, 2007.

. !-(+!-!-86, Fathallah-Shaykh SA (2017) Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies, Pediatr Nephrol Berl Ger, vol.32, pp.743-751

T. H. Jafar, P. C. Stark, and C. H. Schmid, Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease, Kidney Int, vol.60, pp.1131-1140, 2001.

C. Pietrement, E. Allain-launay, and J. Bacchetta, Diagnostic et prise en charge de la maladie rénale chronique de l'enfant : recommandations de la Société de néphrologie pédiatrique (SNP), Arch Pédiatrie, vol.23, pp.1191-1200, 2016.

M. G. Caletti, M. Missoni, and C. Vezzani, Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy, Pediatr Nephrol Berl Ger, vol.26, pp.1247-1254, 2011.

R. Lou-meda, R. S. Oakes, and J. N. Gilstrap, Prognostic significance of microalbuminuria in postdiarrheal hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.22, pp.117-120, 2007.

L. De-petris, A. Gianviti, and U. Giordano, Blood pressure in the long-term follow-up of children with hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.19, pp.1241-1244, 2004.

R. T. Krmar, J. R. Ferraris, and J. A. Ramirez, Ambulatory blood pressure monitoring after recovery from hemolytic uremic syndrome, Pediatr Nephrol Berl Ger, vol.16, pp.812-816, 2001.

J. S. Vansickle, T. Srivastava, and A. Us, Risk Factors for Short-and Long-Term Outcomes in Children With STEC-HUS/D+ HUS: A Single-Center Experience, Glob Pediatr Health, vol.5, pp.2333794-18816920, 2018.

L. Vaterodt, J. Holle, and D. Hüseman, Short-and Long-Term Renal Outcome of, 2018.

. Hemolytic-uremic, Syndrome in Childhood. Front Pediatr, vol.6, p.220

R. S. Oakes, J. K. Kirkham, and J. K. Kirkhamm, Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome, 2008.

, Pediatr Nephrol Berl Ger, vol.23, pp.1303-1308

C. Monet-didailler, A. Godron-dubrasquet, and I. Madden, Long-term outcome, 2019.